Serina Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Serina Therapeutics, Inc. (SER) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.22 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-13
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $2.76.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-06-30 was $11.31.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $14.87.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-09-30 was $0.76.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $4.53, a 49.83% decline from fiscal 2024.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $9.03, a 66.22% decline from fiscal 2023.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $26.73, a 3.71% decline from fiscal 2022.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $27.76, a 1801.37% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.22 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $2.76 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | $4.53 10-K · filed 2026-03-25 | ||||
| 2024-12-31 | $9.03 10-K · filed 2025-03-24 | ||||
| 2024-09-30 | $9.16 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $11.31 10-Q · filed 2024-08-09 | $11.72 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $14.87 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | $26.73 10-K · filed 2024-03-22 | ||||
| 2023-09-30 | $0.76 10-Q · filed 2023-11-14 | $0.76 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | $27.76 10-K · filed 2024-03-22 | $0.79 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $0.79 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | $0.71 10-Q · filed 2023-08-14 | $0.79 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $0.80 10-Q · filed 2023-05-12 | ||||
| 2021-12-31 | $1.46 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $1.46 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $1.46 10-Q · filed 2022-08-12 | $1.46 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | $0.53 10-K · filed 2021-03-31 | ||||
| 2019-12-31 | $2.45 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | $1.99 10-K/A · filed 2020-03-31 | ||||
| 2017-12-31 | $1.31 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |